Dietary and botanical anxiolytics

Medical Science Monitor

Volumn 18, Issue 4, 2012, Pages

  Alramadhan, Elham ^a   Hanna, Mirna S ^a   Hanna, Mena S ^b   Goldstein, Todd A ^a   Avila, Samantha M ^a   Weeks, Benjamin S ^a  

^a ADELPHI UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Anxiety; Anxiolytic; Botanical medicine; Kava kava; Nutrition

Indexed keywords

4 AMINOBUTYRIC ACID; 5 HYDROXYTRYPTOPHAN; ALPHA TOCOPHEROL; ANXIOLYTIC AGENT; ARGININE; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CALCIUM; DOPAMINE; GINKGO BILOBA EXTRACT; HYDROCORTISONE; HYPERICUM PERFORATUM EXTRACT; KAVA EXTRACT; LORAZEPAM; LYSINE; MAGNESIUM; NORADRENALIN; OMEGA 3 FATTY ACID; PHENYLALANINE; PLACEBO; SELENIUM; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THEANINE; TRYPTOPHAN; TYROSINE; UNINDEXED DRUG; VITAMIN D; WITHANIA SOMNIFERA EXTRACT;

ANXIETY DISORDER; ARTICLE; BRAIN LEVEL; BREATHING EXERCISE; COGNITIVE THERAPY; DIET SUPPLEMENTATION; DRUG MEGADOSE; GENERALIZED ANXIETY DISORDER; HERB; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OXIDATIVE STRESS; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PREMENSTRUAL SYNDROME; TREATMENT DURATION; VALERIANA OFFICINALIS;

EID: 84859553675     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882608     Document Type: Article

References (141)

1. Kessler RC, Ruscio AM, Shear K, Wittchen HU: Epidemiology of anxiety disorders. Curr Top Behav Neurosci, 2010; 2: 21-35
2. Kessler RC, Berglund PA, Demler O et al: Lifetime prevalence and ageof-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry, 2005; 62(6): 593-602
3. Kessler RC, Chiu WT, Demler O, Walters EE: Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry, 2005; 62(6): 617-27
4. Bulloch AG, Currie S, Guyn L et al: Estimates of the treated prevalence of bipolar disorders by mental health services in the general population: comparison of results from administrative and health survey data. Chronic Dis Inj Can, 2011; 31(3): 129-34
5. Roberson-Nay R, Kendler KS: Panic disorder and its subtypes: a comprehensive analysis of panic symptom heterogeneity using epidemiological and treatment seeking samples. Psychol Med, 2011: 1-11
6. Culpepper L: Generalized anxiety disorder and medical illness. J Clin Psychiatry, 2009; 70(Suppl.2): 20-24
7. Goodwin RD, Davidson KW, Keyes K: Mental disorders and cardiovascular disease among adults in the United States. J Psychiatr Res, 2009; 43(3): 239-46
8. Gureje O: Comorbidity of pain and anxiety disorders. Curr Psychiatry Rep, 2008; 10(4): 318-22
9. Ringbäck Weitoft G, Rosén M: Is perceived nervousness and anxiety a predictor of premature mortality and severe morbidity? A longitudinal follow up of the Swedish survey of living conditions. J Epidemiol Community Health, 2005; 59(9): 794-98
10. Weisberg RB: Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry, 2009; 70(Suppl.2): 4-9
11. Wyrwich KW, Harnam N, Revicki DA et al: Assessment of quality of life enjoyment and satisfaction questionnaire-short form responder thresholds in generalized anxiety disorder and bipolar disorder studies. Int Clin Psychopharmacol, 2011; 26(3): 121-29
12. Roy-Byrne PP, Wagner AW, Schraufnagel TJ: Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry, 2005; 66(Suppl.4): 16-22
13. Bienvenu OJ, Wuyek LA, Stein MB: Anxiety disorders diagnosis: some history and controversies. Curr Top Behav Neurosci, 2010; 2: 3-19
14. Merlo LJ, Storch EA: Obsessive-compulsive disorder: tools for recognizing its many expressions. J Fam Pract, 2006; 55(3): 217-22
15. Machado-de-Sousa JP, Arrais KC, Alves NT et al: Facial affect processing in social anxiety: tasks and stimuli. J Neurosci Methods, 2010; 193(1): 1-6
16. Coelho CM, Gonçalves DC, Purkis H et al: Specific phobias in older adults: characteristics and differential diagnosis. Int Psychogeriatr, 2010; 22(5): 702-11
17. Cantor C: Post-traumatic stress disorder: evolutionary perspectives. Aust N Z J Psychiatry, 2009; 43(11): 1038-48
18. Risbrough V: Behavioral correlates of anxiety. Curr Top Behav Neurosci, 2010; 2: 205-28
19. Hunot V, Churchill R, Silva de Lima M, Teixeira V: Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev, 2007; (1): CD001848
20. Tolin DF: Is cognitive-behavioral therapy more effective than other therapies? A meta-analytic review. Clin Psychol Rev, 2010; 30(6): 710-20
21. Durant C, Christmas D, Nutt D: The pharmacology of anxiety. Curr Top Behav Neurosci, 2010; 2: 303-30
22. Cloos JM, Ferreira V: Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry, 2009; 22(1): 90-95
23. Bourin M, Lambert O: Pharmacotherapy of anxious disorders. Hum Psychopharmacol. 2002; 17(8): 383-400
24. Fernstrom JD, Fernstrom MH: Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr, 2007; 137(6 Suppl.1): 1539S-47S; discussion 1548S
25. Hood SD, Hince DA, Davies SJ et al: Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology (Berl), 2010; 208(2): 223-32
26. Toker L, Amar S, Bersudsky Y et al: The biology of tryptophan depletion and mood disorders. Isr J Psychiatry Relat Sci, 2010; 47(1): 46-55
27. Belcaro G, Cesarone MR, Cornelli U, Dugall M: MF Afragil® in the treatment of 34 menopause symptoms: a pilot study. Panminerva Med, 2010; 52(2 Suppl.1): 49-54
28. Roiser JP, Levy J, Fromm SJ et al: The effect of acute tryptophan depletion on the neural correlates of emotional processing in healthy volunteers. Neuropsychopharmacology, 2008; 33(8): 1992-2006
29. Feurté S, Gerozissis K, Regnault A, Paul FM: Plasma Trp/LNAA ratio increases during chronic ingestion of an alpha-lactalbumin diet in rats. Nutr Neurosci, 2001; 4(5): 413-18
30. Trachte GJ, Uncini T, Hinz M: Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population. Neuropsychiatr Dis Treat, 2009; 5: 227-35
31. Croonenberghs J, Verkerk R, Scharpe S et al: Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controls. Life Sci, 2005; 76(19): 2171-83
32. Ruhe HG, Mason NS, Schene AH: Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry, 2007; 12: 331-59
33. Rot M, Mathew SJ, Charney DS: Links Neurobiological mechanisms in major depressive disorder. CMAJ, 2009; 180(3): 305-13
34. Young SN: How to increase serotonin in the human brain without drugs. J Psychiatry Neurosci, 2007; 32(6): 394-99
35. Young SN, Leyton M: The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. Pharmacol Biochem Behav, 2002; 71(4): 857-65
36. Lakhan SE, Vieira KF. Nutritional therapies for mental disorders. Nutr J, 2008; 7: 2
37. Ghosh S, Smriga M, Vuvor F et al: Effect of lysine supplementation on health and morbidity in subjects belonging to poor peri-urban households in Accra, Ghana. Am J Clin Nutr, 2010; 92(4): 928-39
38. Smriga M, Ghosh S, Mouneimne Y et al: Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in Northwest Syria. Proc Natl Acad Sci USA, 2004; 101(22): 8285-88
39. Smriga M, Ando T, Akutsu M et al: Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans. Biomed Res. 2007; 28(2): 85-90
40. Carroll D, Ring C, Suter M, Willemsen G: The effects of an oral multivitamin combination with calcium, magnesium, and zinc on psychological well-being in healthy young male volunteers: a double-blind placebo-controlled trial. Psychopharmacology (Berl), 2000; 150(2): 220-25
41. De Souza MC, Walker AF, Robinson PA, Bolland K: A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med, 2000; 9(2): 131-39
42. Hanus M, Lafon J, Mathieu M: Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin, 2004; 20(1): 63-71
43. Sartori SB, Landgraf R, Singewald N: The clinical implications of mouse models of enhanced anxiety. Future Neurol, 2011; 6(4): 531-71
44. Benton D, Cook R: Selenium supplementation improves mood in a double-blind crossover trial. Psychopharmacology (Berl), 1990; 102(4): 549-50
45. Benton D, Cook R: The impact of selenium supplementation on mood. Biol Psychiatry, 1991; 29(11): 1092-98
46. Mokhber N, Namjoo M, Tara F et al: Effect of supplementation with selenium on postpartum depression: a randomized double-blind placebo-controlled trial. J Matern Fetal Neonatal Med, 2011; 24(1): 104-8
47. Gosney MA, Hammond MF, Shenkin A, Allsup S: Effect of micronutrient supplementation on mood in nursing home residents. Gerontology, 2008; 54(5): 292-99
48. Bargellini A, Piccinini L, De Palma M et al: Trace elements, anxiety and immune parameters in patients affected by cancer. J Trace Elem Med Biol, 2003;17(Suppl.1): 3-9
49. Shor-Posner G, Lecusay R, Miguez MJ et al: Psychological burden in the era of HAART: impact of selenium therapy. Int J Psychiatry Med, 2003; 33(1): 55-69
50. Perica MM, Delas I: Essential Fatty acids and psychiatric disorders. Nutr Clin Pract, 2011; 26(4): 409-25
51. Ross BM Omega-3 polyunsaturated fatty acids and anxiety disorders. Prostaglandins Leukot Essent Fatty Acids, 2009; 81(5-6): 309-12
52. Appleton KM, Rogers PJ, Ness AR: Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr Res Rev, 2008; 21(1): 13-41
53. Kiecolt-Glaser JK, Belury MA, Andridge R et al: Omega-3 supplementation lowers inflammation and anxiety in medical students: A randomized controlled trial. Brain Behav Immun, 2011; 25(8): 1725-34
54. Buydens-Branchey L, Branchey M, Hibbeln JR: Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog Neuropsychopharmacol Biol Psychiatry, 2008; 32(2): 568-75
55. Hughes RN, Lowther CL, van Nobelen M: Prolonged treatment with vitamins C and E separately and together decreases anxiety-related openfield behavior and acoustic startle in hooded rats Pharmacol Biochem Behav, 2011; 97(3): 494-99
56. Brody S: High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial. Biol Psychiatry, 2002; 52(4): 371-74
57. Ambrogini P, Ciuffoli S, Lattanzi D et al: Maternal dietary loads of atocopherol differentially influence fear conditioning and spatial learning in adult offspring. Physiol Behav, 2011; 104(5): 809-15
58. Kalueff AV, Lou YR, Laaksi I, Tuohimaa P: Increased anxiety in mice lacking vitamin D receptor gene. Neuroreport, 2004; 15(8): 1271-74
59. Armstrong DJ, Meenagh GK, Bickle I et al: Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clin Rheumatol, 2007; 26(4): 551-54
60. Weeks BS: Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian. Med Sci Monit, 2009; 15(11): RA256-62
61. Head KA, Kelly GS: Nutrients and botanicals for treatment of stress: adrenal fatigue, neurotransmitter imbalance, anxiety, and restless sleep. Altern Med Rev, 2009; 14(2): 114-40
62. Chiappedi M, Bejor M: Herbals and natural dietary supplements in psychiatric practice. Recent Pat CNS Drug Discov, 2010; 5(2): 164-71
63. Saeed SA, Bloch RM, Antonacci DJ: Herbal and dietary supplements for treatment of anxiety disorders. Am Fam Physician, 2007; 76(4): 549-56
64. van der Watt G, Laugharne J, Janca A: Complementary and alternative medicine in the treatment of anxiety and depression. Curr Opin Psychiatry, 2008; 21(1): 37-42
65. Sarris J, Kavanagh DJ: Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med, 2009; 15(8): 827-36
66. Linde K: St. John's wort - an overview. Forsch Komplementmed, 2009; 16(3): 146-55
67. Linde K, Berner MM, Kriston L: St John's wort for major depression. Cochrane Database Syst Rev, 2008; (4): CD000448
68. Ara I, Bano S: St. John's Wort modulates brain regional serotonin metabolism in swim stressed rats. Pak J Pharm Sci, 2009; 22(1): 94-101
69. Tadros MG, Mohamed MR, Youssef AM et al: Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: a possible role of hyperforin. Behav Brain Res, 2009; 199(2): 334-39
70. Canning S, Waterman M, Orsi N et al: The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS Drugs, 2010; 24(3): 207-25
71. van Die MD, Bone KM, Burger HG et al: Effects of a combination of Hypericum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. J Altern Complement Med, 2009; 15(9): 1045-48
72. Mannel M, Kuhn U, Schmidt U et al: St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial. J Psychiatr Res, 2010; 44(12): 760-67
73. Walesiuk A, Braszko JJ: Preventive action of Ginkgo biloba in stressand corticosterone-induced impairment of spatial memory in rats. Phytomedicine, 2009; 16(1): 40-46
74. Kuribara H, Weintraub ST, Yoshihama T, Maruyama Y: An anxiolyticlike effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice. J Nat Prod, 2003; 66(10): 1333-37
75. Woelk H, Arnoldt KH, Kieser M, Hoerr R: Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res, 2007; 41(6): 472-80
76. Faustino TT, de Almeida RB, Andreatini R: Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies. Rev Bras Psiquiatr, 2010; 32(4): 429-36
77. Mishra LC, Singh BB, Dagenais S: Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev, 2000; 5(4): 334-46
78. Mohan L, Rao US, Gopalakrishna HN, Nair V: Evaluation of the Anxiolytic Activity of NR-ANX-C (a Polyherbal Formulation) in Ethanol Withdrawal-Induced Anxiety Behavior in Rats. Evid Based Complement Alternat Med, 2011; 2011. pii: 327160
79. Kulkarni SK, Singh K, Bishnoi M: Comparative behavioural profile of newer antianxiety drugs on different mazes. Indian J Exp Biol, 2008; 46(9): 633-38
80. Ramanathan M, Balaji B, Justin A: Behavioural and neurochemical evaluation of Perment an herbal formulation in chronic unpredictable mild stress induced depressive model. Indian J Exp Biol, 2011; 49(4): 269-75
81. Andrade C: Ashwagandha for anxiety disorders. World J Biol Psychiatry, 2009; 10(4 Pt 2): 686-87
82. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S: Anxiolyticantidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine, 2000; 7(6): 463-69
83. Cooley K, Szczurko O, Perri D et al: Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974. PLoS One, 2009; 4(8): e6628
84. Saeed SA, Bloch RM, Antonacci DJ: Safety of kava for patients with mild anxiety disorders. Am Fam Physician, 2008; 78(4): 433-34
85. Sarris J, Kavanagh DJ, Byrne G et al: The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl), 2009; 205: 399-407
86. Sarris J, Kavanagh DJ, Deed G, Bone KM: St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. Hum Psychopharmacol, 2009; 24(1): 41-48
87. Scherer J: Kava-kava extract in anxiety disorders: an outpatient observational study. Advances in Therapy, 1997; 15: 261-69
88. Volz HP, Kieser M: Kava-kava extract WS 1490 versus placebo in anxiety disorders - a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry, 1997; 30(1): 1-5
89. Boerner RJ, Sommer H, Berger W et al: Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder - an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine, 2003; 10: 38-49
90. Watkins LL, Connor KM, Davidson JR: Effect of kava extract on vagal cardiac control in generalized anxiety disorder: preliminary findings. J Psychopharmacol, 2001; 15: 283-86
91. Malsch U, Kieser M: Efficacy of kava-kava in the treatment of nonpsychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl), 2001; 157: 277-83
92. Cagnacci A, Arangino S, Renzi A et al: Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas, 2003; 44: 103-9
93. Boerner RJ: Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia. Phytother Res, 2001; 15: 646-47
94. Ortiz JG, Nieves-Natal J, Chavez P: Effects of Valeriana offi cinalis extractson [3H]fl unitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res, 1999; 24(11): 1373-78
95. Awad R, Levac D, Cybulska P et al: Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol, 2007; 85(9): 933-42
96. Yuan CS, Mehendale S, Xiao Y et al: The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg, 2004; 97(2): 353-58
97. Khom S, Baburin I, Timin E et al: Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specifi city. Neuropharmacology, 2007; 53(1): 178-87
98. Trauner G, Khom S, Baburin I et al: Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med, 2008; 74(1): 19-24
99. Benke D, Barberis A, Kopp S et al: GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. 2009; 56(1): 174-81
100. Hadjikhani R: Anxiolytic-like Effects of Dichloromethane Extracts of Valerian (DEV) in Adult Male Wistar Rats. World Academy of Science, Engineering and Technology, 2009; (55): 532-36
101. Hattesohl M, Feistel B, Sievers H et al: Extracts of Valeriana offi cinalis L.s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine, 2008; 15(1-2): 2-15
102. Andreatini R, Sartori VA, Seabra ML, Leite JR: sEffect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res, 2002; 16(7): 650-54
103. Muller SF, Klement S: A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine, 2006; 13(6): 383-87
104. Bhattacharyya D, Jana U, Debnath PK, Sur TK: Initial exploratory observational pharmacology of Valeriana wallichii on stress management: a clinical report. Nepal Med Coll J, 2007; 9(1): 36-39
105. Kennedy DO, Little W, Haskell CF, Scholey AB: Anxiolytic effects of a combination of Melissa officinalis and Valeriana offi cinalis during laboratory induced stress. Phytother Res, 2006; 20(2): 96-102
106. Nemeroff CB: The role of GABA in thepathophysiology and treatment of anxiety disorders. Psychopharmacol Bull, 2003; 37: 133-46
107. Kendell SF, Krystal JH, Sanacora G: GABA andglutamate systems as therapeutic targets in depressionand mood disorders. Expert Opin Ther Targets, 2005; 9: 153-68
108. Kugaya A, Sanacora G: Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr, 2005; 10: 808-19
109. Bazil CW, Battista J, Basner RC: Gabapentinimproves sleep in the presence of alcohol. J Clin SleepMed, 2005; 1: 284-87
110. Abdou AM, Higashiguchi S, Horie K et al: Relaxation and immunity enhancement effects of gamma aminobutyric acid (GABA) administration in humans. Biofactors, 2006; 26(3): 201-8
111. Thorne Research, Inc: Gamma-Aminobutyric Acid (GABA). Altern Med Rev, 2007; 12(3): 274-79
112. Heese T, Jenkinson J, Love C et al: Anxiolytic effects of L-theanine - a component of green tea - when combined with midazolam, in the male Sprague-Dawley rat. AANA J, 2009; 77(6): 445-49
113. Rogers PJ, Smith JE, Heatherley SV, Pleydell-Pearce CW: Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology (Berl), 2008; 195(4): 569-77
114. Kakuda T: Neuroprotective effects of theanine and its preventive effects on cognitive dysfunction. Pharmacol Res, 2011; 64(2): 162-68
115. Cho HS, Kim S, Lee SY et al: Protective effect of the green tea component, L-theanine on environmental toxins-induced neuronal cell death. Neurotoxicology, 2008; 29(4): 656-62
116. Lu K, Gray MA, Oliver C et al: The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol, 2004; 19(7): 457-65
117. Koetter U, Schrader E, Kaufeler R, Brattstrom A: A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother Res, 2007; 21(9): 847-51
118. Dimpfel W, Suter A: Sleep improving effects of a single dose administration of a valerian/hops fluid extract - a double blind, randomized, placebo-controlled sleep-EEG study in a parallel design using electrohypnograms. Eur J Med Res, 2008; 13(5): 200-4
119. Kennedy DO, Little W, Scholey AB: Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med, 2004; 66(4): 607-13
120. Dimpfel W, Pischel I, Lehnfeld R: Effects of lozenge containing lavender oil, extracts from hops, lemon balm and oat on electrical brain activityof volunteers. Eur J Med Res, 2004; 9(9): 423-31
121. Wolfson P, Hoffmann DL: An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med, 2003; 9(2): 74-78
122. Movafegh A, Alizadeh R, Hajimohamadi F et al: Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg, 2008; 106(6): 1728-32
123. Amsterdam JD, Li Y, Soeller I, Rockwell K et al: A randomized, doubleblind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol, 2009; 29(4): 378-82
124. Kalman DS, Feldman S, Feldman R et al: Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial. Nutr J, 2008; 7: 11
125. Bystritsky A, Kerwin L, Feusner JD: A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med, 2008; 14(2): 175-80
126. Cunningham J, Yonkers KA, O'Brien S, Eriksson E: Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry, 2009; 17(2): 120-37
127. Parcells DA: Women's mental health nursing: depression, anxiety and stress during pregnancy. J Psychiatr Ment Health Nurs, 2010; 17(9): 813-20
128. Bloch M, Azem F, Aharonov I et al: GnRH-agonist induced depressive and anxiety symptoms during in vitro fertilization-embryo transfer cycles. Fertil Steril, 2011; 95(1): 307-9
129. Sundermann EE, Maki PM, Bishop JR: A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition. Menopause, 2010; 17(4): 874-86
130. Kikuchi H, Nakatani Y, Seki Y et al: Decreased blood serotonin in the premenstrual phase enhances negative mood in healthy women. J Psychosom Obstet Gynaecol, 2010; 31(2): 83-89
131. Cubeddu A, Giannini A, Bucci F et al: Paroxetine increases brain-derived neurotrophic factor in postmenopausal women. Menopause, 2010; 17(2): 338-43
132. Jezova D, Hlavacova N: Endocrine factors in stress and psychiatric disorders: focus on anxiety and salivary steroids. Ann NY Acad Sci, 2008; 1148: 495-503
133. Froy O: Cytochrome P450 and the biological clock in mammals. Curr Drug Metab, 2009; 10(2): 104-15
134. Saavedra M, Contreras CM, Azamar-Arizmendi G, Hernández-Lozano M: Differential progesterone effects on defensive burying and forced swimming tests depending upon a gradual decrease or an abrupt suppression schedules. Pharmacol Biochem Behav, 2006; 83(1): 130-35
135. Binder G, Weber S, Ehrismann M et al., And the South German Working Group for Pediatric Endocrinology: Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a doubleblind, randomized, placebo-controlled phase III trial. J Clin Endocrinol Metab, 2009; 94(4): 1182-90
136. Abdali K, Khajehei M, Tabatabaee HR: Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. Menopause, 2010; 17(2): 326-31
137. Michel JL, Chen Y, Zhang H et al: Estrogenic and serotonergic butenolides from the leaves of Piper hispidum Swingle (Piperaceae). J Ethnopharmacol, 2010; 129(2): 220-26
138. Lee J, Kim KW, Kim HK et al: The effect of Rexflavone (Sophorae fructus extract) on menopausal symptoms in postmenopausal women: a randomized double-blind placebo controlled clinical trial. Arch Pharm Res, 2010; 33(4): 523-30
139. Lipovac M, Chedraui P, Gruenhut C et al: Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts. Maturitas, 2010; 65(3): 258-61
140. Ishiwata N, Melby MK, Mizuno S, Watanabe S: New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause, 2009; 16(1): 141-48
141. Mucci M, Carraro C, Mancino P et al: Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause. Minerva Ginecol, 2006; 58(4): 323-34